Syngene International Ltd
NSE:SYNGENE

Watchlist Manager
Syngene International Ltd Logo
Syngene International Ltd
NSE:SYNGENE
Watchlist
Price: 655.65 INR 0.04% Market Closed
Market Cap: 263.4B INR

Syngene International Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Syngene International Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Syngene International Ltd
NSE:SYNGENE
Revenue
₹37.5B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Divi's Laboratories Ltd
NSE:DIVISLAB
Revenue
₹100.3B
CAGR 3-Years
3%
CAGR 5-Years
10%
CAGR 10-Years
N/A
A
Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Revenue
₹41.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Onesource Specialty Pharma Ltd
NSE:ONESOURCE
Revenue
₹14.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sai Life Sciences Ltd
NSE:SAILIFE
Revenue
₹16.9B
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
Anthem Biosciences Ltd
NSE:ANTHEM
Revenue
₹18.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Syngene International Ltd
Glance View

In the bustling landscape of the global pharmaceutical industry, Syngene International Ltd. stands out as a beacon of scientific innovation and strategic acumen. Founded in 1993, this Bangalore-based contract research and manufacturing organization (CRMO) has carved a niche by seamlessly blending cutting-edge research with commercial savvy. Syngene offers integrated services spanning the entire drug discovery and development continuum, catering to diverse sectors including pharmaceuticals, biotechnology, nutrition, animal health, consumer goods, and specialty chemicals. By providing end-to-end solutions, from target identification and discovery chemistry to pre-clinical and clinical development and up to commercial manufacturing, Syngene ensures that its clients can focus on their core competencies, thus accelerating their journey from lab to market. Syngene's revenue model thrives on fostering long-term partnerships with global giants such as Bristol-Myers Squibb, Amgen, and Baxter, who rely on the company's deep scientific expertise and robust infrastructure. By offering bespoke solutions that address specific client needs, Syngene generates income through flexible, multi-year contracts and milestone payments at various stages of the drug development cycle. This approach not only ensures a steady revenue stream but also strengthens Syngene's reputation as a trusted partner in scientific innovation. With their state-of-the-art facilities and a team of world-class scientists, Syngene effectively marries scientific curiosity with business excellence, driving the future of health sciences and securing its position as a pivotal player in the CRMO field.

SYNGENE Intrinsic Value
533.38 INR
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Syngene International Ltd's Revenue?
Revenue
37.5B INR

Based on the financial report for Sep 30, 2025, Syngene International Ltd's Revenue amounts to 37.5B INR.

What is Syngene International Ltd's Revenue growth rate?
Revenue CAGR 5Y
13%

Over the last year, the Revenue growth was 9%. The average annual Revenue growth rates for Syngene International Ltd have been 10% over the past three years , 13% over the past five years .

Back to Top